CTOs on the Move

Prescos

www.prescos.com

 
Prescos is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.prescos.com
  • 3550 General Atomics Ct
    San Diego, CA USA 92121
  • Phone: 858.452.2001

Executives

Name Title Contact Details

Similar Companies

Southwest FLA Regional Imaging

Southwest FLA Regional Imaging is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syndax

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.

Lumos Diagnostics

Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.

Primmune Therapeutics

Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.

Lab Co Inc

Lab Co Inc is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.